Design Therapeutics Inc. (NASDAQ: DSGN) Stock Information | RedChip

Design Therapeutics Inc. (NASDAQ: DSGN)


$6.2700
+0.0600 ( +0.80% ) 18.9K

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Market Data


Open


$6.2700

Previous close


$6.2100

Volume


18.9K

Market cap


$347.37M

Day range


$6.1150 - $6.2900

52 week range


$2.2450 - $7.7700

SEC Filings


Form Type Description Pages Date
8-k 8K-related 13 Mar 19, 2024
10-k Annual reports 96 Mar 19, 2024
4 Insider transactions 1 Jan 05, 2024
4 Insider transactions 1 Jan 05, 2024
4 Insider transactions 1 Dec 05, 2023
4 Insider transactions 1 Dec 05, 2023

Latest News